In humanitarian settings, tailoring community engagement interventions for gender, language, and local culture improves communities’ uptake with interventions. Measures taken to prevent and respond to COVID-19 pandemic such as confinement may increase GBV, especially domestic violence and Intimate... Partner Violence (IPV). This document is meant as a starting point for the field colleagues to support them in ensuring communication to communities around COVID-19 includes gender-based violence (GBV).
more
This note provides a few ideas to a challenging problem of reaching survivors who cannot easily access phone-based GBV support. It is very much a living document given the evolving nature of the pandemic and may be adapted as more evidence, insights and lessons become available. It is intended to sp...ark conversation in the hope that additional contributions and innovations from others will result.
more
This note provides information and practical guidance to support gender-based violence (GBV) practitioners to integrate attention to disability into GBV prevention, risk mitigation and response efforts during the COVID-19 pandemic. This document complements other resources relating to GBV and COVID-...19 and assumes that the user is already familiar with common GBV prevention, risk mitigation and response approaches.
more
COVID-19 has turned the world upside down. Everything has been impacted. How we live and interact with each other, how we work and communicate, how we move around and travel. Every aspect of our lives has been affected.
The goal of the global outbreak response for monkeypox is to stop human-to-human transmission of monkeypox, with a priority focus on communities at high risk of exposure which may differ according to context, and to effectively use strong public health measures to prevent onward spread of the diseas...e. Judicious use of vaccines can support this response. This interim guidance, developed with the advice and support of the Strategic Advisory Group of Experts (SAGE) Working Group on smallpox and monkeypox vaccines, provides the first WHO recommendations on vaccines and immunization for monkeypox. Key points follow.
more
Buruli ulcer is a disease caused by the bacterium Mycobacterium ulcerans. It mainly affects the skin but can also affect the bone. Cases are generally seen in the tropics, primarily in West Africa and Australia.
Infection often leads to ulcers on the arms or legs, which can also destroy skin or sof...t tissue. When not properly treated, the disease can cause irreversible deformity or long-term functional disability.
more
The aim of this course is to improve the prevention, detection, treatment and cure of sexually transmitted infections (STIs) and other reproductive tract infections (RTIs) in settings serving pregnant women and their families.
A critical building block to achieving the global goal of universal hand hygiene by 2030 is adequate levels of funding. Understanding the costs of implementing hand hygiene plans is an essential precursor to fund allocation. This tool aims to provide country-specific cost estimates of achieving univ...ersal hand hygiene in households by 2030. It has been developed jointly by WHO and UNICEF, through a consultancy with WASHeconomics, and with input from the London School of Hygiene and Tropical Medicine, the World Bank and WaterAid
more
Antimicrobial resistance (AMR) is one of the top 10 global public health threats facing humanity. AMR threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi.
It occurs when microorganisms develop resistance to me...dicines that are relied upon for treatment, making some conditions difficult or impossible to cure. As a result, infections persist in the body, increasing the risk of disease spread, severe illness and death.
The Antimicrobial Resistance channel offers learning resources to support implementation of the Global Action Plan on AMR (2015), by building health care worker competencies to help combat AMR in their daily clinical practice.
more
How do they work in an ICC to prevent or mitigate nosocomial infections?
Are you clear that we can all do something to avoid them?
A simple hand wash can make a difference.
Inés Lavega has a degree in nursing and worked for more than 8 years at the CTI of Hospital Maciel, the first public hospit...al in Uruguay.
She tells us about the intense work of nursing, to control infections.
more
Did you know that they are part of Antimicrobial Resistance?
Are you clear that we can all do something to avoid them?
Marcelo Barbato, intensive care physician and Director of the ICU at Hospital Maciel, the first public hospital in Uruguay with a long history in infection control, tells us.
Podcast spotify. Superbugs and you
This policy brief aims to provide a review of the current progress on implementing the Kenya national action plan on AMR, identifies critical gaps, and highlights findings to accelerate further progress in the human health sector. The target audience includes all those concerned with implementing ac...tions to combat antimicrobial resistance in Kenya.
more
In 1997, the Fiftieth World Health Assembly adopted resolution WHA50.29 on the elimination of
lymphatic filariasis as a public health problem. Preliminary guidance from WHO printed in 2011 referred to “verification” as the official process by which the achievements of the Global Programme to El...iminate Lymphatic Filariasis (GPELF) would be confirmed. For the sake of harmonization, the terminology now used for elimination of lymphatic filariasis as a public health problem is “validation”. In 2015, the WHO Strategic and Technical Advisory Group for Neglected Tropical Diseases endorsed standardized processes for confirming and acknowledging success for all neglected tropical diseases targeted for eradication, elimination of transmission, or elimination as a public health problem.
more
We are pleased to provide an editorial to introduce this series of articles on the achievements of the Global Programme to Eliminate Lymphatic Filariasis (GPELF) over the last 2 decades. We
are delighted that so many of the major players in this journey have agreed to contribute to this supplement,... which tracks the successes and identifies the challenges faced over 2 decades of
work as well as also looking towards the coming years.
more
Many countries have made significant progress in the implementation of World Health Organization recommended preventive chemotherapy strategy, to eliminate lymphatic filariasis (LF). However, pertinent challenges such as the existence of areas of residual infections in disease endemic districts pose... potential threats to the achievements made. Thus, this study was undertaken to assess the importance of these areas in implementation units (districts) where microfilaria (MF) positive individuals could not be found during the mid-term assessment after three rounds of mass drug administration.
more
Meeting of the Neglected Tropical Diseases Strategic and Technical Advisory
Group’s Monitoring and Evaluation Subgroup on Disease-specific Indicators
Analysis of microfilaria prevalence data from 430 communities
Lymphatic filariasis (LF), a neglected tropical disease, is targeted for global elimination as a public health problem. This article reviews the history of LF control and elimination activities in the countries of the World Health Organization's (WHO) Eastern Mediterranean Region (EMR) over the last... 2 decades. In 2000, the estimated at-risk population in EMR countries was 12.6 million people, accounting for approximately 1% of the global disease burden. Of the 22 EMR countries, 3 countries (Egypt, Sudan and Yemen) were LF endemic and the disease was suspected in 4 other countries (Djibouti, Oman, Somalia and Saudi Arabia). After almost 2 decades of implementing sustained control and prevention measures, Egypt and Yemen were successfully validated by the WHO as having achieved the elimination criteria in 2017 and 2019, respectively. In 2018, Sudan completed mapping of LF, reaching 26.2% geographical coverage where mass drug administration (MDA) is required and is scaling-up MDA. Extensive epidemiological assessment indicated the absence of LF transmission in the four suspected countries and no MDA required. Challenges faced during the elimination and post-elimination phases are described and discussed
more
In South and Central America, lymphatic filariasis (LF) is caused by Wuchereria bancrofti, which is transmitted by Culex quinquefasciatus, the only vector species in this region. Of the seven countries considered endemic for LF in the Americas in the last decade, Costa Rica, Suriname and Trinidad a...nd Tobago were removed from the World Health Organization list in 2011. The remaining countries, Brazil, Dominican Republic, Guyana and Haiti, have achieved important progress in recent years. Brazil was the first country in the Americas to stop mass drug administration (MDA) and to establish post-MDA surveillance. Dominican Republic stopped MDA in all LF-endemic foci: La Ciénaga and Southwest passed the third Transmission Assessment Survey (TAS) and the Eastern focus passed TAS-1 in 2018. Haiti passed the TAS and interrupted transmission in >80% of endemic communes, achieving effective drug coverage. Guyana implemented effective coverage in MDAs in 2017 and 2018 and in 2019 scaled up the treatment for 100% of the geographical region, introducing ivermectin in the MDA in order to achieve LF elimination by the year 2026. The Americas region is on its way to eliminating LF transmission. However, efforts should be made to improve morbidity management to prevent disability of the already affected populations.
more